Targeting protein prenylation for cancer therapy

Cited by (622)

Items 101–200 of 622

1. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
   the Cancer and Leukemia Group B, Thomas Frank Gajewski, April K.S. Salama, Donna Niedzwiecki, Jeffrey E. Johnson, Gerald P. Linette, Cynthia J. Bucher, Michelle A. Blaskovich, Saı̈d M. Sebti, Frank G. Haluska · 2012 · Journal of Translational Medicine
2. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1
   Smrithi Rajendiran, Anil Vasdev Parwani, Richard J. Hare, Subhamoy Dasgupta, Rhonda K. Roby, Jamboor K. Vishwanatha · 2014 · Molecular Cancer
3. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
   Nam, Gi-Hoon, Kwon, Minsu, Jung, Hanul, Ko, Eunbyeol, Kim, Seong A, Choi, Yoonjeong, Song, Su Jeong, Kim, Seohyun, Lee, Yeji, Kim, Gi Beom et al. · 2021 · Journal for ImmunoTherapy of Cancer
4. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
   Kazi, Aslamuzzaman, Xiang, Shengyan, Yang, Hua, Chen, Liwei, Kennedy, Perry, Ayaz, Muhammad, Fletcher, Steven, Cummings, Christopher, Lawrence, Harshani R., Beato, Francisca et al. · 2019 · Clinical Cancer Research
5. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
   Tang, Daolin, Kroemer, Guido, Kang, Rui · 2021 · Molecular Cancer
6. RAS in pancreatic cancer
   Simone Lanfredini, Asmita Thapa, Eric E. O’Neill · 2019 · Biochemical Society Transactions
7. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions
   William Gillette, Dominic Esposito, Maria Abreu Blanco, Patrick Alexander, Lakshman K. Bindu, Cammi Bittner, Oleg Chertov, Peter H. Frank, Carissa Grose, Jane E. Jones et al. · 2015 · Scientific Reports
8. Dysregulation of Rho GTPases in Human Cancers
   Haiyoung Jung, Suk Ran Yoon, Jeewon Lim, Hee Jun Cho, Hee Gu Lee · 2020 · Cancers
9. Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
   Guo, Christina, Chénard-Poirier, Maxime, Roda, Desamparados, de Miguel, Maria, Harris, Samuel J, Candilejo, Irene Moreno, Sriskandarajah, Priya, Xu, Wen, Scaranti, Mariana, Constantinidou, Anastasia et al. · 2020 · The Lancet Oncology
10. Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer
    Tanya Todorova Kwan, Florian J. Bock, Paul Chang · 2015 · Trends in Molecular Medicine
11. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
    Brian R. Untch, Vanessa Dos Anjos, María E.R. García-Rendueles, Jeffrey A. Knauf, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena, Umesh Kumar Bhanot, Nicholas D. Socci, Alan Loh Ho, Ronald A. Ghossein et al. · 2018 · Cancer Research
12. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway
    Yanli Yao, Lishuang Zhou, Wenfeng Liao, Huanjun Chen, Zhenyun Du, Chenghao Shao, Peipei Wang, Kan Ding · 2018 · Carbohydrate Polymers
13. Protein prenylation and human diseases: a balance of protein farnesylation and geranylgeranylation
    Na Xu, Ning Shen, Xiuxing Wang, Shan Jiang, Bin Xue, Chaojun Li · 2015 · Science China Life Sciences
14. Direct Modulation of Small GTPase Activity and Function
    Philipp M. Cromm, Jochen Spiegel, Tom N. Grossmann, Herbert Waldmann · 2015 · Angewandte Chemie International Edition
15. Structure, catalysis, and inhibition mechanism of prenyltransferase
    Hsin‐Yang Chang, Tien‐Hsing Cheng, Andrew H.‐J. Wang · 2020 · IUBMB Life
16. Global proteomic analysis of prenylated proteins in Plasmodium falciparum using an alkyne-modified isoprenoid analogue
    Kiall F. Suazo, Chad Schaber, Charuta C. Palsuledesai, Audrey R. Odom John, Mark Dewey Distefano · 2016 · Scientific Reports
17. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
    Strand, Matthew S., Krasnick, Bradley A., Pan, Hua, Zhang, Xiuli, Bi, Ye, Brooks, Candace, Wetzel, Christopher, Sankpal, Narendra, Fleming, Timothy, Goedegebuure, S. Peter et al. · 2019 · Oncotarget
18. The Vitamin D Receptor Inhibits the Respiratory Chain, Contributing to the Metabolic Switch that Is Essential for Cancer Cell Proliferation
    Marco Consiglio, Michele Destefanis, Deborah Morena, Valentina Foglizzo, Mattia Forneris, Gianpiero Pescarmona, Francesca Silvagno · 2014 · PLoS ONE
19. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela, Khurshid, Faisal, Lu, Kevin, Woodward, Brian, Husain, Hatim · 2021 · npj Precision Oncology
20. Geranylgeranyl diphosphate synthase (GGPPS) regulates non‐alcoholic fatty liver disease (NAFLD)–fibrosis progression by determining hepatic glucose/fatty acid preference under high‐fat diet conditions
    Jia Liu, Shan Jiang, Yue Zhao, Qian Sun, Jingzi Zhang, Di Shen, Jing Wu, Ning Shen, Xiao Fu, Xitai Sun et al. · 2018 · The Journal of Pathology
21. Development of Synthetic Lethality Anticancer Therapeutics
    Bingliang Fang · 2014 · Journal of Medicinal Chemistry
22. Fermentative production and direct extraction of (−)-α-bisabolol in metabolically engineered Escherichia coli
    Gui Hwan Han, Seong Keun Kim, Paul Kyung-Seok Yoon, Younghwan Kang, Byoung Su Kim, Yaoyao Fu, Heung-Chae Jung, Heung Chae Jung, Dae-Hee Lee, Seon-Won Kim et al. · 2016 · Microbial Cell Factories
23. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
    McMichael, Elizabeth L., Jaime-Ramirez, Alena Cristina, Guenterberg, Kristan D., Luedke, Eric, Atwal, Lakhvir S., Campbell, Amanda R., Hu, Zhiwei, Tatum, Armika S., Kondadasula, Sri Vidya, Mo, Xiaokui et al. · 2017 · Clinical Cancer Research
24. Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections
    Joshua D. Ochocki, Mark Dewey Distefano · 2012 · MedChemComm
25. MCRS1 Binds and Couples Rheb to Amino Acid-Dependent mTORC1 Activation
    Fawal, Mohamad-Ali, Brandt, Marta, Djouder, Nabil · 2015 · Developmental Cell
26. Chemical and Genetic Validation of the Statin Drug Target to Treat the Helminth Disease, Schistosomiasis
    Liliana Rojo‐Arreola, Thavy Long, Daniel E. Asarnow, Brian M. Suzuki, Rahul Singh, Conor R. Caffrey · 2014 · PLoS ONE
27. Membrane-Dependent Modulation of the mTOR Activator Rheb: NMR Observations of a GTPase Tethered to a Lipid-Bilayer Nanodisc
    Mohammad T. Mazhab‐Jafari, Christopher B. Marshall, Peter B. Stathopulos, Yoshihiro Kobashigawa, Vuk Stambolic, Lewis E. Kay, Fuyuhiko Inagaki, Mitsuhiko Ikura · 2013 · Journal of the American Chemical Society
28. Protein Lipidation by Palmitoylation and Myristoylation in Cancer
    Chee Wai Fhu, Azhar Ali · 2021 · Frontiers in Cell and Developmental Biology
29. 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells
    Idrees Mohammed, Shahienaz E. Hampton, Louise Ashall, Emily R. Hildebrandt, Robert A. Kutlik, Surya P. Manandhar, Brandon J. Floyd, Haley E. Smith, Jonathan K. Dozier, Mark Dewey Distefano et al. · 2015 · Bioorganic & Medicinal Chemistry
30. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins
    Rosemary Yu, Joseph Longo, Jenna E. van Leeuwen, Peter Mullen, Wail Ba-Alawi, Benjamin Haibe‐Kains, Linda Z. Penn · 2017 · Cancer Research
31. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells
    Takayuki Hoshii, Atsuo Kasada, Tomoki Hatakeyama, Masashi Ohtani, Yuko Tadokoro, Kazuhito Naka, Tsuneo Ikenoue, Tomokatsu Ikawa, Hiroshi Kawamoto, Hans Jörg Fehling et al. · 2014 · Proceedings of the National Academy of Sciences
32. The involvement of post-translational modifications in cardiovascular pathologies: Focus on SUMOylation, neddylation, succinylation, and prenylation
    Jinning Gao, Kai Shao, Xiatian Chen, Zhe Li, Ziqian Liu, Zhongjie Yu, Lynn Htet Htet Aung, Yin Wang, Peifeng Li · 2019 · Journal of Molecular and Cellular Cardiology
33. Protein Prenylation and Synaptic Plasticity: Implications for Alzheimer’s Disease
    David A. Hottman, Ling Li · 2014 · Molecular Neurobiology
34. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo
    Hiu Yeung Lau, Pondy Murugappan Ramanujulu, Dianyan Guo, Tianming Yang, Melissa Wirawan, Patrick J. Casey, Mei‐Lin Go, Mei Wang · 2014 · Cancer Biology & Therapy
35. Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells
    Mengling Liu, Yingfeng Xia, Jane Ding, Bingwei Ye, Erhu Zhao, Jeong-Hyeon Choi, Ahmet Alptekin, Chunhong Yan, Zheng Dong, Shuang Huang et al. · 2016 · Cell Reports
36. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies
    Zhenfeng Zhang, Stephan Urban · 2020 · Journal of Hepatology
37. Protein Prenylation Drives Discrete Signaling Programs for the Differentiation and Maintenance of Effector Treg Cells
    WEI WEN SU, Nicole M. Chapman, Jun Wei, Hu Zeng, Yogesh Dhungana, Hao Shi, Jordy Saravia, Peipei Zhou, Lingyun Long, Sherri L. Rankin et al. · 2020 · Cell Metabolism
38. Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective
    Jae-Ok Park, Vishal Pandya, Sean J. Ezekiel, Albert Marinus Berghuis · 2021 · Frontiers in Chemistry
39. Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
    Edward W. Tate, Lior Soday, Ana Losada de la Lastra, Mei Wang, Hening Lin · 2024 · Nature reviews. Cancer
40. RAS/RAF/MEK Inhibitors in Oncology
    Massimo Broggini · 2012 · Current Medicinal Chemistry
41. P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance
    Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto, Hirokazu Sugino, Ayumu Yoshikawa, Yutaro Otsuka, Haruka Handa, Yasuhito Onodera, Jin‐Min Nam, Chitose Oneyama et al. · 2016 · The Journal of Cell Biology
42. Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product
    Jaeok Park, Michał Zieliński, Alexandr Magder, Youla S. Tsantrizos, Albert Marinus Berghuis · 2017 · Nature Communications
43. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer
    Vidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, Jamunarani Veeraraghavan, Lanfang Qin, Nicholas Wang, Lukas Mikolaj Simon, Tao Wang, Xiaoyong Fu, Agostina Nardone et al. · 2019 · Molecular Cancer Research
44. A Homogenous Bioluminescent System for Measuring GTPase, GTPase Activating Protein, and Guanine Nucleotide Exchange Factor Activities
    Subhanjan Mondal, Kevin Hsiao, Said A. Goueli · 2015 · Assay and Drug Development Technologies
45. A novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochores
    Devinderjit Kaur Moudgil, Nathan P. Westcott, Jakub K. Famulski, Kinjal Patel, Dawn Macdonald, Howard C. Hang, Gordon K. T. Chan · 2015 · The Journal of Cell Biology
46. Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation
    S Blondel, A.-L. Egesipe, P Picardi, A-L Jaskowiak, Maria Notarnicola, J Ragot, Johana Tournois, Amélie Le Corf, Benjamin Brinon, Pauline Poydenot et al. · 2016 · Cell Death and Disease
47. Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization
    Aleksandra Marchwicka, Daria Kamińska, Mohsen Monirialamdari, K. M. Błażewska, Edyta Gendaszewska‐Darmach · 2022 · International Journal of Molecular Sciences
48. Regulation of protein prenylation
    Dominik Jung, Hagen S. Bachmann · 2023 · Biomedicine & Pharmacotherapy
49. Enantioselective microbial synthesis of the indigenous natural product (−)-α-bisabolol by a sesquiterpene synthase from chamomile (Matricaria recutita)
    Young‐Jin Son, Moonhyuk Kwon, Dae‐Kyun Ro, Soo-Un Kim · 2014 · Biochemical Journal
50. Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V)
    Adam M. Levinson, John H. McGee, Andrew G. Roberts, Gardner S. Creech, Ting Wang, Michael T. Peterson, Ronald C. Hendrickson, Gregory L. Verdine, Samuel J. Danishefsky · 2017 · Journal of the American Chemical Society
51. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
    Nicolas Béry, Abimael Cruz-Migoni, Carole J. R. Bataille, Camilo E. Quevedo, Hanna Tulmin, Ami Miller, Angela J. Russell, Simon E. V. Phillips, Stephen B. Carr, Terence Howard Rabbitts · 2018 · eLife
52. Drug design targeting active posttranslational modification protein isoforms
    Fanwang Meng, Zhongjie T. Liang, Kehao Zhao, Cheng Luo · 2020 · Medicinal Research Reviews
53. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3
    Zhou, Ying, Dang, Jason, Chang, Kung-Yen, Yau, Edwin, Aza-Blanc, Pedro, Moscat, Jorge, Rana, Tariq M. · 2016 · Cancer Research
54. KRAS: A Druggable Target in Colon Cancer Patients
    Francesca Negri, Lorena Bottarelli, Gian Luigi de’Angelis, Letizia Gnetti · 2022 · International Journal of Molecular Sciences
55. Preclinical evaluation of statins as a treatment for ovarian cancer
    Elizabeth Robinson, Mandrita Nandi, Laurelle L. Wilkinson, D. Mark Arrowsmith, Anthony D. M. Curtis, Alan Richardson · 2013 · Gynecologic Oncology
56. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin
    Yifeng Xia, Yi-Liang Liu, Yonghua Xie, Wei Zhu, Francisco Guerra, Shen Shen, Narayana Yeddula, Wolfgang H. Fischer, William Low, Xiaoying Zhou et al. · 2014 · Science Translational Medicine
57. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer
    Sahar Nissim, Ignaty Leshchiner, Joseph Douglas Mancias, Matthew Blake Greenblatt, Ophélia Maertens, Christopher A. Cassa, Jill Anne Rosenfeld, Andrew Graham Cox, John Hedgepeth, Julia I. Wucherpfennig et al. · 2019 · Nature Genetics
58. Oncogenes in melanoma: An update
    Manfred Kunz · 2014 · European Journal of Cell Biology
59. Rce1: mechanism and inhibition
    Shahienaz E. Hampton, Timothy M. Dore, Walter K. Schmidt · 2018 · Critical Reviews in Biochemistry and Molecular Biology
60. How cancer cells remodel lipid metabolism: strategies targeting transcription factors
    Do‐Won Jeong, Seulbee Lee, Yang‐Sook Chun · 2021 · Lipids in Health and Disease
61. Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions
    Elaina A. Zverina, Corissa L. Lamphear, Elia N. Wright, Carol A. Fierke · 2012 · Current Opinion in Chemical Biology
62. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer
    James B. Greenaway, Carl Virtanen, Kata Osz, Tamás Révay, Daniel Barry Hardy, Trevor G. Shepherd, Gabriel E. DiMattia, Jim Petrik · 2016 · Oncotarget
63. A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors
    Thomas Benjamin Karasic, Elena Gabriela Chiorean, Saı̈d M. Sebti, Peter James O'Dwyer · 2019 · Targeted Oncology
64. Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
    Jackie L. Johnson, Smitha Pillai, Srikumar Chellappan · 2012 · Biochemistry Research International
65. RETRACTED ARTICLE: ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation
    Davide Esposito, Ila Pant, Yao Shen, Ruifang Qiao, Xiaobao Yang, Yiyang Bai, Jian Jun Jin, Poulikos I. Poulikakos, Stuart A. Aaronson · 2022 · Nature Communications · Retracted
66. Drug for an 'undruggable' protein
    Nicole M. Baker, Channing J. Der · 2013 · Nature
67. Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases
    Tea Lanišnik Rižner · 2012 · Frontiers in Pharmacology
68. The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice
    Claudia Lanterna, Andrea Musumeci, Laura Raccosta, Gianfranca Corna, Marta Angiola Moresco, Daniela Maggioni, Raffaella Fontana, Claudio Doglioni, Claudio Bordignon, Catia Traversari et al. · 2016 · Cancer Immunology Immunotherapy
69. Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells
    Charuta C. Palsuledesai, Joshua D. Ochocki, Michelle M. Kuhns, Yen-Chih Wang, Janel K. Warmka, Dustin Chernick, Elizabeth V. Wattenberg, Ling Li, Edgar A. Arriaga, Mark Dewey Distefano · 2016 · ACS Chemical Biology
70. Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT
    Melinda M. Diver, Leanne Pedi, Akiko Koide, Shohei Koide, Stephen Barstow Long · 2018 · Nature
71. Enzymes in the Cholesterol Synthesis Pathway: Interactomics in the Cancer Context
    Pavel Ershov, Leonid A. Kaluzhskiy, Yuri V. Mezentsev, Evgeniy O. Yablokov, Oksana V. Gnedenko, Alexis S. Ivanov · 2021 · Biomedicines
72. Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms
    H Y Lau, Jingyi Tang, Patrick J. Casey, Mei Wang · 2017 · Oncogene
73. Blocking Ras inhibition as an antitumor strategy
    Nagore I. Marín‐Ramos, Silvia Ortega‐Gutiérrez, María Luz López-Rodríguez · 2018 · Seminars in Cancer Biology
74. Discovery, biochemical characterization, and bioengineering of cyanobactin prenyltransferases
    Yuchen Zhang, Yuki Goto, Hiroaki Suga · 2022 · Trends in Biochemical Sciences
75. A Zebrafish Chemical Suppressor Screening Identifies Small Molecule Inhibitors of the Wnt/β-catenin Pathway
    Naoyuki Nishiya, Yusuke Oku, Yusuke Kumagai, Yuki Sato, Emi Yamaguchi, Akari Sasaki, Momoko Shoji, Yukimi Ohnishi, Hitoshi Okamoto, Yoshimasa Uehara · 2014 · Chemistry & Biology
76. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
    Sergey G. Klochkov, Неганова Маргарита Евгеньевна, Nagendra Sastry Yarla, Madhukiran Parvathaneni, Bechan Sharma, Vadim V. Tarasov, George Emilio Barreto, Сергей Олегович Бачурин, Ghulam Md Ashraf, Gjumrakch M. Aliev · 2017 · Seminars in Cancer Biology
77. Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibition in Cancer Treatment
    Judyta Zabielska, Tomasz Śledziński, Ewa Stelmańska · 2019 · Anticancer Research
78. The role of KRAS splice variants in cancer biology
    Cristina Nuevo‐Tapioles, Mark R. Philips · 2022 · Frontiers in Cell and Developmental Biology
79. Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease
    Ling Li, Wei Zhang, Shaowu Cheng, Dongfeng Cao, Marc A. Parent · 2012 · Molecular Neurobiology
80. Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
    Jennifer E. Howes, Denis T. Akan, Michael C. Burns, Olivia W. Rossanese, Alex G. Waterson, Stephen W. Fesik · 2018 · Molecular Cancer Therapeutics
81. Simvastatin interferes with cancer ‘stem-cell’ plasticity reducing metastasis in ovarian cancer
    Sumie Kato, MF Liberona, Javier Cerda‐Infante, M Sánchez, J Henríquez, Carolina Bizama, Martha Lía Gaviria Bravo, Pamela González, R. Gejman, Jorge A. Brañes et al. · 2018 · Endocrine Related Cancer
82. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
    Hye Won Lee, Jason K. Sa, Antonio Gualberto, Catherine Rose Scholz, Hyun Hwan Sung, Byong Chang Jeong, Han Yong Choi, Ghee Young Kwon, Se Hoon Park · 2020 · Clinical Cancer Research
83. Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases
    Leanna R. Gentry, Akiyuki Nishimura, Adrienne D. Cox, Timothy D. Martin, Denis Tsygankov, Motohiro Nishida, Timothy C. Elston, Channing J. Der · 2015 · Journal of Biological Chemistry
84. Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms
    Saeideh Nakhaei‐Rad, Fereshteh Haghighi, Parivash Nouri, Soheila Rezaei Adariani, Jana Lissy, Neda S. Kazemein Jasemi, Radovan Dvorský, Mohammad Reza Ahmadian · 2018 · Critical Reviews in Biochemistry and Molecular Biology
85. Post-translational Modifications (PTMs), from a Cancer Perspective: An Overview
    B. Sharan Sharma, Vaishna Prabhakaran, Akash P Desai, Jaya Bajpai, Ramtej Jayram Verma, Prabodha K. Swain · 2019 · Oncogen
86. Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
    Woo-Jin Lim, Mingyu Lee, Yerin Oh, Xue-Quan Fang, Sujin Lee, Chang-Hoon Lim, Jooho Park, Ji-Hong Lim · 2021 · Cells
87. Light-Responsive Polyion Complex Micelles with Switchable Surface Charge for Efficient Protein Delivery
    Qiao Jin, Tongjiang Cai, Yin Wang, Haibo Wang, Jian Ji · 2014 · ACS Macro Letters
88. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras
    Chris J. Novotny, Gregory L. Hamilton, Frank P. McCormick, Kevan M. Shokat · 2017 · ACS Chemical Biology
89. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease
    Yue Zhao, Tianyu Wu, Mengfei Zhao, Chaojun Li · 2020 · Journal of Biological Chemistry
90. The Pivotal Role of the Dysregulation of Cholesterol Homeostasis in Cancer: Implications for Therapeutic Targets
    Etienne Ho Kit Mok, Terence K. Lee · 2020 · Cancers
91. Mevalonate metabolism governs cancer immune surveillance
    Georg Gruenbacher, Martin Thurnher · 2017 · OncoImmunology
92. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
    Xie, Chun, Li, Ying, Li, Lan-Lan, Fan, Xing-Xing, Wang, Yu-Wei, Wei, Chun-Li, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun · 2017 · Frontiers in Pharmacology
93. The Cys Sense: Thiol Redox Switches Mediate Life Cycles of Cellular Proteins
    Meytal Radzinski, Tal Oppenheim, Norman Metanis, Dana Reichmann · 2021 · Biomolecules
94. Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors
    Andrew Jon Holland, Rita M. Reis, Sherry Niessen, Cláudia Pereira, Douglas Andres, H. Peter Spielmann, Don W. Cleveland, Arshad B. Desai, Reto Gassmann · 2015 · Molecular Biology of the Cell
95. Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals
    Aline C. C. A. Gomes, Angélica Lauria do Nascimento Mello, Manuel Gustavo Leitão Ribeiro, Diogo Gomes Garcia, Clóvis Orlando da Fonseca, Marcela d'Alincourt Salazar, Axel H. Schönthal, Thereza Quírico‐Santos · 2017 · Archivum Immunologiae et Therapiae Experimentalis
96. Challenges in Ras therapeutics in pancreatic cancer
    Minsig Choi, Harold Bien, Adaobi Mofunanya, Scott Powers · 2017 · Seminars in Cancer Biology
97. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
    Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodríguez, John M. Gross, Amy N. Allen, Xiaolin Wan et al. · 2022 · Oncogene
98. Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
    Jonathan K. Dozier, Santoshkumar L. Khatwani, James W. Wollack, Yen-Chih Wang, Claudia Schmidt‐Dannert, Mark Dewey Distefano · 2014 · Bioconjugate Chemistry
99. Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
    Joachim Rudolph, Jeff Settleman, Shiva Malek · 2021 · Cancer Discovery
100. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
     Robert Jr. Roskoski · 2021 · Pharmacological Research